113 related articles for article (PubMed ID: 17015894)
21. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.
Burkett BJ; Bartlett DJ; McGarrah PW; Lewis AR; Johnson DR; Berberoğlu K; Pandey MK; Packard AT; Halfdanarson TR; Hruska CB; Johnson GB; Kendi AT
Radiol Imaging Cancer; 2023 Jul; 5(4):e220157. PubMed ID: 37477566
[TBL] [Abstract][Full Text] [Related]
22. Imaging Characteristics of Meningiomas.
Galldiks N; Hattingen E; Langen KJ; Tonn JC
Adv Exp Med Biol; 2023; 1416():21-33. PubMed ID: 37432617
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of [
Hertelendi M; Belguenani O; Cherfi A; Folitar I; Kollar G; Polack BD
Biomedicines; 2023 Mar; 11(4):. PubMed ID: 37189646
[TBL] [Abstract][Full Text] [Related]
24. Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis.
Ottolino-Perry K; Mealiea D; Sellers C; Acuna SA; Angarita FA; Okamoto L; Scollard D; Ginj M; Reilly R; McCart JA
Mol Ther Oncolytics; 2023 Jun; 29():44-58. PubMed ID: 37180034
[TBL] [Abstract][Full Text] [Related]
25. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A
Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355
[TBL] [Abstract][Full Text] [Related]
26. Lutathera
Urso L; Nieri A; Uccelli L; Castello A; Artioli P; Cittanti C; Marzola MC; Florimonte L; Castellani M; Bissoli S; Porto F; Boschi A; Evangelista L; Bartolomei M
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111596
[TBL] [Abstract][Full Text] [Related]
27. Response to Peptide Receptor Radionuclide Therapy in Pheocromocytomas and Paragangliomas: A Systematic Review and Meta-Analysis.
Marretta AL; Ottaiano A; Iervolino D; Bracigliano A; Clemente O; Di Gennaro F; Tafuto R; Santorsola M; Lastoria S; Tafuto S
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836029
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models.
Ullrich M; Richter S; Liers J; Drukewitz S; Friedemann M; Kotzerke J; Ziegler CG; Nölting S; Kopka K; Pietzsch J
Theranostics; 2023; 13(1):278-294. PubMed ID: 36593963
[TBL] [Abstract][Full Text] [Related]
29. Response to targeted radionuclide therapy with [
Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
Front Endocrinol (Lausanne); 2022; 13():957172. PubMed ID: 36339441
[TBL] [Abstract][Full Text] [Related]
30. Somatostatin Receptor Theranostics for Refractory Meningiomas.
Salgues B; Graillon T; Horowitz T; Chinot O; Padovani L; Taïeb D; Guedj E
Curr Oncol; 2022 Aug; 29(8):5550-5565. PubMed ID: 36005176
[TBL] [Abstract][Full Text] [Related]
31. Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review.
Okano A; Miyawaki S; Teranishi Y; Ohara K; Hongo H; Sakai Y; Ishigami D; Nakatomi H; Saito N
Neurol Med Chir (Tokyo); 2022 Aug; 62(8):347-360. PubMed ID: 35871574
[TBL] [Abstract][Full Text] [Related]
32. Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma.
Carrasquillo JA; Chen CC; Jha A; Pacak K; Pryma DA; Lin FI
J Nucl Med; 2021 Sep; 62(9):1192-1199. PubMed ID: 34475242
[TBL] [Abstract][Full Text] [Related]
33. Personalized Management of Pheochromocytoma and Paraganglioma.
Nölting S; Bechmann N; Taieb D; Beuschlein F; Fassnacht M; Kroiss M; Eisenhofer G; Grossman A; Pacak K
Endocr Rev; 2022 Mar; 43(2):199-239. PubMed ID: 34147030
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.
Patel M; Tena I; Jha A; Taieb D; Pacak K
Front Endocrinol (Lausanne); 2021; 12():625312. PubMed ID: 33854479
[TBL] [Abstract][Full Text] [Related]
35. Metastatic Pheochromocytomas and Abdominal Paragangliomas.
Granberg D; Juhlin CC; Falhammar H
J Clin Endocrinol Metab; 2021 Apr; 106(5):e1937-e1952. PubMed ID: 33462603
[TBL] [Abstract][Full Text] [Related]
36. From Diagnosis to Therapy-PET Imaging for Pheochromocytomas and Paragangliomas.
Patel HV; Srivastava A; Becker MD; Beninato T; Laird AM; Singer EA
Curr Urol Rep; 2021 Jan; 22(1):2. PubMed ID: 33403502
[TBL] [Abstract][Full Text] [Related]
37.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
38. Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma.
Wu W; Zhou Y; Wang Y; Liu L; Lou J; Deng Y; Zhao P; Shao A
Front Oncol; 2020; 10():1633. PubMed ID: 33014821
[TBL] [Abstract][Full Text] [Related]
39. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma.
Ilanchezhian M; Jha A; Pacak K; Del Rivero J
Curr Treat Options Oncol; 2020 Aug; 21(11):85. PubMed ID: 32862332
[TBL] [Abstract][Full Text] [Related]
40. Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas.
Jimenez C; Subbiah V; Stephen B; Ma J; Milton D; Xu M; Zarifa A; Akhmedzhanov FO; Tsimberidou A; Habra MA; Rodon Anhert J; Fu S; Naing A
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
